Replies to post #424043 on Amarin Corp Plc (AMRN)

[couldbebetter]

I hope Denner will use it to interest a BP in using Vascepa as an adjunct drug for all cancer
treatments or therapies.

[TalShu]

Captain,

Thank you for keeping us abreast on PREPARE RCT (PRevention Using EPA Against coloREctal).

As a reminder, Amarin’s Form 10-K 2022 for the year ending December 31, 2021 asserts that the Company "owns" "one additional patent related to the use of VASCEPA to treat prostate cancer with a term that expires in 2037."